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Summary Asthma is a chronic inflammatory disease, which is characterised by
reversible airflow obstruction in response to a variety of stimuli. Exacerbations in
response to airway irritants are part of the natural history of asthma, but often they
also represent a failure in chronic treatment. Presentations to emergency
departments and other acute care settings are common and frequently lead to
hospitalisation and other complications. After treatment, however, most patients
are discharged to the care of their primary care physician for further management.
This review highlights the role of systemic and inhaled corticosteroids as mainstays
of treatment in the acute and sub-acute phase of an exacerbation. These agents
form the basis of most current clinical practice guidelines, yet their use is not
universal. We will review the evidence for the use of these agents that arises from
the Cochrane Collaboration of Systematic Reviews contained in the Cochrane
Library.
& 2004 Elsevier Ltd. All rights reserved.
Introduction to acute asthma
Asthma is an important healthcare problem world-
wide. Over 27 million people in the USA have at
some time received a diagnosis of asthma, and the
attack prevalence (those experiencing an emer-
gency department visit for an exacerbation in the
past year) is about 1.8 million.1 Although asthma
affects more children than adults, the burden of
illness is high in both groups, and the costs
associated with asthma are staggering. In 1998,
the indirect and direct expenditures for asthma
exceeded 12 billion dollars in the USA.2 In Canada,
the cost reached $600 million; 25% of these costs
were expended on acute care of asthma (emer-
gency department visits and hospitalisation).3
Emergency department visits are estimated to cost
$324 (Canadian dollars) a visit and more than twice
that amount a day for hospitalisation.2
Emergency department presentations are pre-
cipitated by many factors, but the most common
reasons include a superimposed upper respiratory
tract infection, environmental allergens or poor
control of chronic asthma. Emergency visits are
important events for asthmatics and families, as
they represent a vulnerable point in the illness and
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are associated with significant morbidity, patient
and parent apprehension and occasional mortality.
For these reasons, the assessment and treatment of
acute asthma has been the focus of considerable
research and efforts to develop clinical practice
guidelines.4,5 Despite the many national attempts
to standardise and improve asthma care, wide gaps
still remain between what is known to be effective
treatment and what is practised.6 The discrepancy
can be attributed mainly to physician variation in
asthma diagnosis and lack of clarity in treatment
options for this common disorder. This review
outlines the role of airway inflammation in the
presentation of acute asthma and the effect of
corticosteroids (both inhaled and systemic) in
successful treatment.7
Cochrane Airway Group reviews
Selecting the most effective treatment of acute
asthma has been the subject of considerable study;
nevertheless, unlike other areas of cardio-respira-
tory care, many of the studies are small and the
evidence conflicting. This paper attempts to
summarise research results on the main anti-
inflammatory agents used in the treatment of
asthma during an exacerbation. In doing so, we
will rely heavily on systematic review evidence
from a number of important studies published in
the Cochrane Database of Systematic Reviews, an
electronic publication of the Cochrane Collabora-
tion. In particular, we will focus on the data
available in the reviews compiled by the Airway
Review Group. These have been routinely regarded
as high quality and have been extensively quoted.8
These systematic reviews use standardised and
rigorous methods to summarise and combine the
best evidence from individual randomised con-
trolled trials pertaining to a specific topic area.
The results represent Level I evidence for treat-
ment decisions.9
Corticosteroids
Some of the first controlled clinical trials in acute
asthma were conducted in the UK in the late 1950s
using corticosteroids (CS), one of the first effective
therapeutic agents for asthma. Today, there is a
large body of research in this field that is at times
conflicting and difficult to understand. Before
embarking on an examination of the clinical
literature to attempt to resolve the confusion,
some definitions are necessary. Throughout this
discussion, the term ‘systemic corticosteroid’ (SCS)
refers to oral, intramuscular or intravenous routes
of corticosteroid administration. SCS will be con-
trasted to ‘inhaled corticosteroids’ (ICS), which
includes the following: corticosteroid medication
taken by metered dose inhaler, with or without a
spacer, dry powder inhaler or nebuliser. We should
also point out that since the emergence of inhaled
agents, a gradual change in preferred route has
occurred. Although SCS were the mainstay of
treatment for many years, they have now largely
been replaced by ICS for the initial and preferred
treatment of chronic asthma. It is important to
note that the literature on SCS in the treatment of
acute asthma is older and often methodologically
weaker than that involving ICS agents. This will
be discussed in the context of the Cochrane
Collaboration.
Inflammation and Corticosteroids
There have been many mechanisms proposed to
explain the effect of corticosteroids on airway
inflammation; however, this venue does not provide
the opportunity to explain them all in detail.
Overall, research suggests that systemic corticos-
teroids suppress multiple components of allergic
and non-allergic airway inflammation, including
cell recruitment, adhesion molecule expression or
release, airway permeability and production of
cytokines potentially involved in airway immunity
or remodelling.10
Traditional pharmacology teaching suggested
that CS agents enter the cell and attach to steroid
receptors affecting protein synthesis. This mechan-
ism was thought to require many hours to produce a
measurable effect. However, there is mounting
evidence that there is more than one specific
mechanism to explain the CS effects observed in
asthma.
Clearly, the full effects of corticosteroids are not
seen immediately, and this is important.10 SCSs
prevent the amplification of the inflammatory
cascade. Specifically, they interfere with the
synthesis of inflammatory mediators and prevent
migration or activation of inflammatory cells. They
are thought to up-regulate the beta-receptor,
resulting in improved bronchodilation. At the
cellular level, they change the expression of
genes, and this mechanism explains the observation
that their effect occurs over a longer period of
time.
In addition, there seems to be another mechan-
ism that may account for effects obtained over a
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shorter period. CS agents are graded on strength
based on their blanching effect, and this early
effect seems to be related to vascular activity. Non-
specific vascular effects at the level of the airway
may result in vasoconstriction, a decrease in
capillary membrane permeability, and may also
decrease mucous production. In both mechanisms,
once the inflammatory reaction has been initiated,
corticosteroids do not affect the mediators that
have already been released.
The short-term effect, especially observed with
inhaled agents, has been found in other airway
diseases. Many investigators have now confirmed
the rapid onset of action of inhaled corticosteroids
in croup, another ‘airway’ disease common in the
emergency department setting.11 It is likely that a
similar role may be in played by CS agents in the
treatment of acute asthma.12 The mechanisms for
this CS effect would be similar to those outlined
previously for SCSs in general; however, the role of
direct vasoconstriction may be more important
using the inhaled route. Some basic science
evidence suggests that another mechanism to
explain the action of ICSs involves decreased
recruitment of inflammatory precursors from
bone marrow to the lung.13,14 This is very promis-
ing research, and provides further evidence to
suggest that the action of ICS and SCS may be
different.
Emergency department care
The overall goal of emergency department care is
to provide safe and effective treatment for the
bronchospasm associated with the acute presenta-
tion and then to initiate effective anti-inflamma-
tory treatment. Early treatment of acute asthma
has generally focused on the use of inhaled (usually
through a nebuliser) short-acting b2-agonists be-
cause of their undisputed and rapid effect on
relieving bronchospasm and associated breathing
dysfunction. There is increasing support, particu-
larly in children, for adding anticholinergic agents
(ipratropium bromide [IB]) to b2-agonist therapy in
moderate to severe exacerbations.15,16 In another
Cochrane review, in which beta-agonist and sys-
temic corticosteroids were given to all patients,
the addition of intravenous magnesium sulfate
(MgSO4) reduced hospitalisation (odds ratio
[OR]¼ 0.1; 95% CI: 0.04–0.27) and improved pul-
monary functions (mean increase in peak expira-
tory flow: 52 l/min; 95% CI: 27–77) in severe asthma
exacerbations.17 Considerable differences in pa-
tient factors, emergency department treatment
and discharge care for patients with asthma have
been found between Canada and USA.17 It is likely
that similar differences could be demonstrated
between North America and other non-North
American locations.
In addition to the treatments that address
immediate bronchoconstriction, early use of anti-
inflammatories is a cornerstone of appropriate
treatment. The approaches described below should
reduce the need for hospitalisation and ensure that
patients receive the appropriate treatment re-
quired to prevent relapse and reduce the potential
for a serious negative outcome (e.g. intubation or
death).
Systemic corticosteroids
The airway oedema and increased secretions
associated with the inflammation in acute asthma
can be effectively treated with SCS. The early use
(i.e. within 90min of arrival) of SCS delivered by
either oral or intravenous (IV) routes is a principal
treatment choice in published evidence-based
asthma guidelines.4,5 A meta-analysis investigating
this issue determined that the early use of SCS for
acute asthma in the emergency department sig-
nificantly reduced admission rates compared with
placebo (Fig. 1; OR¼ 0.50; 95% CI: 0.31–0.81); with
the NNT being 8 (95% CI: 5–20).18 This benefit was
more pronounced for those not already receiving
corticosteroids (OR¼ 0.37; 95% CI: 0.19–0.70) and
those experiencing a severe exacerbation
(OR¼ 0.35; 95% CI: 0.21–0.59). The effects of SCS
on pulmonary functions were variable in the short
term, mainly due to insufficient reporting of
results. Side-effect profiles were similar between
all SCS treatment routes and placebo, suggesting
that emergency department treatment with SCS is
safe.
There has been some debate over the use
of IV versus oral corticosteroids in the emergency
department; however, this now seems to be
focused on identifying which patients require
the IV route compared with the oral route. There
is no evidence from controlled trials or meta-
analyses to suggest the advantage offered by
corticosteroids in moderate to severe asthma is
related to the route of administration. Further
systematic review evidence on dosing suggests that
high-dose corticosteroids, at least in hospitalised
patients, are no more effective than moderate and
low doses.19
Applying this information to practice requires a
clear understanding that not all levels of severity
have been assessed with sufficient rigor to confirm
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equivalency of systemic routes. Until further
evidence is available, it seems reasonable to select
oral agents as the first-line choice while reserving
IV corticosteroids for individuals who are too
dyspneic to swallow, are obtunded or intubated or
are unable to tolerate oral medications (e.g.
vomiting). It is not important what corticosteroid
agent or dose (e.g. high, moderate or low) is
provided,19 as long as SCS is administered early.
The decision on SCS delivery should be based on
cost, availability and patient factors (Table 1). The
main issue to remember is the need to start
systemic corticosteroids early and consistently for
patients with moderate to severe acute asthma.
Inhaled corticosteroids
Although inhaled corticosteroids are usually con-
sidered a treatment for chronic asthma, emerging
evidence supports their use in the emergency
department setting for acute asthma. A Cochrane
systematic review on this topic12 suggests that
using ICS early in the emergency for acute asthma
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Figure 1 Systematic review evidence for reducing admissions in acute asthma using early systemic corticosteroids.
Table 1 Anti-inflammatory drugs and doses commonly used in the treatment of acute asthma.
Drug Adult dose Paediatric dose
Systemic corticosteroids
Hydrocortisone
(Solucortef; in ED)
250–500mg IV 5–10mg/kg IV (max: 250mg)
Methyl-prednisolone
(Solumedrol; in ED)
80–125mg IV 1–2mg/kg IV (max:125mg)
4mg/kg IM
Prednisone (in ED) 40–50mg po 1mg/kg po (max: 50mg)
Prednisolone (in ED) Limited evidence 2mg/kg po
Dexamethasone (in ED) Limited evidence 10mg IM or
Prednisone (at discharge) 40–50mg po qd for 5–10 days;
tapering not required)
1–2mg/day divided bid or qd for
5–7 days; tapering not required)
Inhaled corticosteroids
Budesonide (in ED) 1–2mg nebulised Limited evidence; 1–2mg nebulised
Fluticasone (in ED) 500–1000 lg/dose Limited evidence
Flunisolide (in ED) Up to 2 g/h X 6 h Limited evidence
Budesonide (at discharge) 800–1600 lg/day for up to 21 days Limited evidence
Fluticasone (at discharge) 500–1000 lg/day for up to 21 days Limited evidence
Flunisolide (at discharge) Up to 2000 lg/day for up to 21 days Limited evidence
Bid, twice a day; ED, emergency department; IM, intramuscular; IV, Intravenous; limited evidence, untested in this setting; po,
by mouth; qd, every day.
278 B.H. Rowe et al.
reduces admissions (Fig. 2; OR¼ 0.33; 95% CI: 0.17,
0.64) and improves pulmonary function (mean
increase in peak expiratory flow: 8.0%; 95% CI: 3–
13) compared with placebo. However, in several of
the studies included in this review, systemic
corticosteroids were not given to either the
treatment or control group, thus limiting the power
of the review to determine the additive benefit of
ICS in this setting.
A recent study found that there may be draw-
backs to replacing systemic corticosteroids with ICS
in the treatment of acute asthma.20 In this
randomised double-blind study, patients received
ICS versus oral corticosteroids in addition to
standard 2-agonist therapy. Participants treated
with oral corticosteroids experienced better out-
comes and were admitted less frequently than
participants treated with ICS. Combined with the
previous meta-analysis data (Fig. 3), these results
suggest that ICS may be useful as an adjunct to
systemic corticosteroids, but not as a replacement
choice.12,21 Additional research is needed in this
area to determine the optimal dose, frequency and
drug to be used, and to clarify the magnitude of the
additional benefit when ICS are being given
concurrently with SCS.
Post-emergency department care
The goal of post-emergency department care is to
return each patient to a level of functioning
commensurate with the current definition of
asthma ‘control’. According to some national
guidelines, control means that the patient is using
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Figure 2 Systematic review evidence for reducing admissions in acute asthma using inhaled corticosteroids. ICS,
inhaled corticosteroids.
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Figure 3 Systematic review evidence for admission when replacing systemic with inhaled corticosteroids in acute
asthma. ICS, inhaled corticosteroids.
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rescue beta-agonists less than four times a week, is
sleeping through the night and is performing their
regular daily activities (e.g. work and exercise)
without limitations resulting from asthma.4 Achiev-
ing these goals would require that patients receive
the appropriate treatment (e.g. medications,
education, and compliance discussion) required
to prevent or attenuate the next exacerbation of
asthma.
Post-emergency department systemic
corticosteroids
About 12–17% of patients treated for acute asthma
in the emergency department will relapse within 2
weeks of discharge, many because of unresolved
inflammation that leaves the airways sensitive to
inhaled irritants.22,23 Guidelines strongly encourage
treatment with systemic corticosteroids after dis-
charge from the emergency department for an
asthma exacerbation to reduce this high risk of
relapse.4,5 Compelling evidence for this approach is
found in a Cochrane systematic review comparing
post-emergency department CS treatment to pla-
cebo.22 Significantly fewer patients in the corticos-
teroid group relapsed in the first week compared
with placebo (Fig. 4; OR¼ 0.35; 95% CI: 0.17–0.73).
This reduced risk continued over the first 21 days
(OR¼ 0.33; 95% CI: 0.13, 0.82). The corticosteroid
group also had less need for b2-agonists (mean
difference: three less activations per 24 h; 95%
CI: –5.5 to –1.0). Changes in pulmonary function
tests and side-effects, while rarely reported, failed
to demonstrate differences between the treatment
groups.
A subgroup analysis indicated that intra-muscular
(IM) corticosteroids and a 7–10-day tapering course
of corticosteroids were similarly effective. IM
therapy may be best reserved for patients with
questionable compliance, inability to afford the
price of an oral prescription or those who are
otherwise unreliable (i.e. cognitive impairment
intoxication). The review established that the
associated NNT was 13 (95% CI: 7–91) treated
patients to prevent one relapse after an exacerba-
tion of asthma.22–24
Small sample sizes in the RCTs conducted to date
did not permit an examination of the relative
effectiveness of various regimens, and definitive
recommendations concerning dose or dosing proto-
col(s) cannot be provided. However, a 40–50mg
dose (prednisone equivalent) of oral corticosteroid
once a day for a short period (5–10 days) seems
appropriate for most patients discharged with an
acute asthma episode; this dose will also improve
compliance. The need to ‘taper’ a short course of
oral corticosteroids seems unwarranted,25,26 espe-
cially when ICSs are being used concurrently.27
Post-emergency department inhaled
corticosteroids
In US emergency departments, most patients with
acute asthma are discharged and prescribed a short
course (5–7 days) of oral corticosteroids. Less
information is available on the use of inhaled
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Figure 4 Systematic review evidence for reducing relapses after discharge in acute asthma using systemic
corticosteroids. CS, corticosteroids.
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corticosteroids; however, available data indicate
impressive practice variation in ICS use after
emergency department discharge. For example, in
US sites associated with a large North American
emergency department airway research network
(http://healthcare.partners.org/marc), only 25%
of discharged patients were prescribed an inhaled
corticosteroid if they were not already regularly
taking one28 whereas, in Canadian sites, more than
50% of similar patients were treated with an ICS at
discharge.29
Emerging evidence supports the use of combined
inhaled and oral corticosteroids upon discharge from
the emergency department.27 Two published ran-
domised controlled trials27,30 and one abstract,31
when pooled, result in a favourable effect.32
The pooled effect shows a trend in favour of the
ICS plus oral corticosteroid group having fewer
relapses after discharge than the oral corticoster-
oid alone group (Fig. 5; OR¼ 0.68; 95% CI: 0.46–
1.02).32 The lack of clear benefit may be surprising
to some readers; however, remember there were
only three known trials in this review, and the
heterogeneity may be explained by either trial
quality or dosing of agents. In the only study
demonstrating clear benefit, the dose was con-
siderably higher than in the other two.33 Further
research on the appropriate dose of ICS agent is
clearly needed. Clinically, the results of this review
indicate that clinicians should counsel patients
already taking ICS about compliance.34–36
Considering that many of the patients with acute
asthma who present to the emergency department
show features associated with poorly controlled
chronic asthma,36 they represent vulnerable pa-
tients who are ideal candidates for inhaled corti-
costeroids. In fact, treatment of asthma with ICS in
such patients is the key to ‘regaining control’ over
the longer term. Consequently, one could argue
that those patients not already taking ICS agents
should be considered for long-term inhaled therapy
in conjunction with oral prednisone after dis-
charge. In most studies, ‘long-term’ implies treat-
ment for at least 3 weeks; however, chronic
therapy may be indicated in many patients on the
basis of the underlying severity of the disease and
the control of symptoms after treatment. For
patients with more severe illness, adding ICS to
oral corticosteroids would clearly be the optimal
treatment strategy.
The dose and duration of inhaled and oral
corticosteroids should be based on recent history
of symptom control, healthcare utilisation and
quality-of-life indicators. Evidence is particularly
conflicting in the area of ICS. For example, a recent
administrative database study examining patients
who were discharged from the emergency depart-
ment suggested that a prescription for ICS signifi-
cantly reduced relapses; however, the prescribed
dose did not seem to influence outcome.37 In addi-
tion, Australian investigators completed a systema-
tic review confirming the flat dose–response ICS
curve in chronic asthma.38 In the systematic re-
view,32 subgroup evidence shows that higher doses
of inhaled corticosteroids may be more effective.
Given this information, it would seem that treat-
ment must be individualised and the lowest does at
which control is maintained targeted.37,38
Several recent publications have examined the
effect of replacing oral corticosteroids with high-
dose ICS. These generally compare oral prednisone
to very high doses of ICS in acute mild asthma after
discharge. Although the systematic review failed to
demonstrate a significant difference in asthma
relapse between the two treatments (OR ¼ 1.0;
95% CI: 0.48–1.42), these results need to be
interpreted cautiously.32 Although the evidence
implies equivalence, these results are not conclu-
sive owing to the width of the confidence intervals
and the inclusion of only patients with mild asthma
exacerbations. Given the limited data on this issue
to date, use of ICS alone should be reserved for
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Figure 5 Systematic review evidence for reducing relapses after discharge in acute asthma using inhaled
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patients with very mild asthma exacerbations and
patients who refuse or cannot take oral corticos-
teroids. Compared with the traditional short course
of prednisone, ICS are expensive and more difficult
for patients and families to use. Given that there is
potential for added benefit with combined therapy,
future research should focus on this important
comparison.
Discussion
This paper examined the evidence for the use of
corticosteroids in acute asthma, mainly systematic
reviews contained in the Cochrane Library. Although
there are exciting advances being made in chronic
asthma care with the introduction of long-acting
beta-agonists39 and leukotriene modifiers,40 further
evidence of effectiveness are required before
recommending them as substitutes or adjuncts to
inhaled and systemic corticosteroids in the emer-
gency department or after discharge. Until there is
sound evidence for their use, these newer inter-
ventions will remain secondary considerations.
Furthermore, there is evidence that non-pharma-
cologic interventions, such as limited education,41
asthma self-management programmes,42 regular
medical review42 and appropriate referrals to
specialists, may be effective in curbing the burden
of acute asthma in the emergency department.
Acute exacerbations represent an opportunity for
clinicians to review the longer-term pharmacologi-
cal and non-pharmacological management of asth-
ma. Adhering to an asthma plan to maintain long-
term control is often problematic, especially in the
areas of regular medication use and avoiding
environmental triggers. The opportunity to intro-
duce or reinforce helpful behaviours should not be
lost. Given that asthma is a chronic disease, acute
care physicians should encourage patients, when-
ever practical, to seek regular, longitudinal care for
their asthma.
Conclusion
Asthma is a common, chronic and often debilitating
disease. The treatment approaches to control
bronchial inflammation summarised in this review
provide hope for an early return to activities,
reduced symptoms and improved quality of life in
the sub-acute period after an exacerbation. Com-
bining self-management skills and educational
interventions with appropriate preventive medica-
tion provides patients with the best opportunity to
maintain their optimal health status, and prevent
an exacerbation or relapse in the future.
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PRACTICE POINTS
* Provision of systemic corticosteroids in the
emergency department reduces admissions
to hospital from acute asthma.
* Dose and delivery method for systemic
corticosteroids in the emergency depart-
ment seem less important than early
initiation.
* Discharge plans, including systemic corti-
costeroids, reduce relapses from acute
asthma after discharge.
* Most acute asthma patients require the
addition of inhaled corticosteroids to sys-
temic corticosteroids after discharge;
plans should be individualised.
* Review of preventive medication compli-
ance and strategies to improve compliance
should be discussed in the emergency
department.
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RESEARCH DIRECTIONS
* The role of different doses of inhaled
corticosteroids after discharge with acute
asthma requires further study.
* The role of newer agents (leukotriene
modifiers and long-acting beta agonists),
in combination with systemic and inhaled
corticosteroids, requires further study.
* The role of clinical practice guidelines in
improving the uptake of the use of
systemic and inhaled corticosteroids re-
quires further study.
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